Interaction between bevacizumab and murine VEGF-A: a reassessment.
about
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesisNormalization of the vasculature for treatment of cancer and other diseases.Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.The "inherent vice" in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively.Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survivalAnti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain.The effect of nicotine on anti-vascular endothelial growth factor therapy in a mouse model of neovascular age-related macular degenerationEffect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion.Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats.A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo.Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo.Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat modelSelective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenograftsMurine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3)Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure.Bevacizumab revisited: its use in different mouse models of ocular pathologies.Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts.Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab.Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model.VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutationsImproved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.Genetically engineered mouse models in cancer researchAnti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurityVascular endothelial growth factor mediates corneal nerve repair.Scaffold-based delivery of a clinically relevant anti-angiogenic drug promotes the formation of in vivo stable cartilageVEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer.Corneal neovascularization during experimental fungal keratitis.Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.VEGF as a Paracrine Regulator of Conventional Outflow Facility.Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.Mechanisms of age-related macular degeneration and therapeutic opportunities.Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.Novel vascular endothelial growth factor blocker improves cellular viability and reduces hypobaric hypoxia-induced vascular leakage and oedema in rat brain.
P2860
Q27000351-D5BE381A-741E-47D2-98D2-BE2A45D31BBFQ28280138-8A2030A2-A9EC-4961-A736-DFC353A8D000Q30471456-A9A9FEF9-162F-4045-B110-019E66FF03EFQ30651989-7BD42F9A-367A-47C4-8A1E-E8651E5C35C4Q33725650-C40B7E45-79FD-4D6B-B4E5-4E754D523274Q33845555-046CD21D-5A4E-48D2-B9A2-B66A4F7D9085Q34054649-4416E773-A8F5-4406-9345-6DB3BDCC6EA4Q34076104-C60B1654-1AC1-4E7C-97EC-E8739748C00BQ34083555-942DD485-9D82-4267-BFBE-745F61C57A4CQ34160549-88A9BEBA-0333-4F82-A6AB-DDEEA79B83E9Q34208338-301F97F0-F3C4-4353-8CB7-5F70851CC587Q34347733-C9407D02-569B-4983-8A21-8067FB473DB3Q34441618-EA3E13C7-5543-4DEA-8B1B-565BE13E0254Q34652557-B735A750-DB84-4588-89B9-E8C04E6E774BQ34682223-B507D395-33FE-44BC-A912-7FD1992B410DQ34973743-4AA49CC4-EB6B-49F5-8C9C-557B04EA3F65Q35028461-40D2C28A-1452-43C1-8A7E-4F13542B9AA9Q35108066-92F5D0BE-3D01-4A3E-96D2-11EF5CF84C5FQ35143121-711FD261-B84A-4F22-A05E-B058F3972096Q35191520-2EF9EB3E-DCE0-4390-836C-090CBEB48F86Q35213093-36D7B887-792D-4182-A59F-17BDD4114DDFQ35223791-845EC641-386B-493A-B935-227007D2E95AQ35358884-84F5A205-870E-40A7-89DD-F7D56203302FQ35646547-68F85242-9C0B-4A11-828C-3A3D435396C9Q35864213-94E53959-A0C3-4F56-9F20-0A8EAF65A101Q35941562-2825DEBD-06F8-4D2A-8452-70C55073B537Q36216197-F5178D10-E540-4F2A-9838-D23E4B625FDBQ36484434-2DD62011-1420-46C7-B7BB-3E756D2B61C4Q36497718-CD28C725-2F41-48D9-B65F-F344A13FCD82Q36752978-D4D478A1-6F02-4B40-AFA2-0F5ECA66D718Q37051762-39AA4480-6E10-4876-A3D4-92E4C8E65E6DQ37052301-B0F8BD18-0F6C-48B7-A2C9-CDD1D32EAB39Q37276919-CA73D64D-619F-44F3-8D4E-315C1D7C4389Q37373833-222B3743-29BD-408A-AC53-7A0D641B7518Q37425259-D6E6F5C3-0F6D-4834-AAE7-D21C155D70ECQ37731916-097878A9-7156-4B9E-BAA2-BC0E30E65F47Q37997765-3595533A-2810-4A6E-810E-B93276B94EB7Q38150757-A39DE1C1-3057-43F4-BAC4-439B063F14F8Q38778205-D2395322-2A14-428F-93B2-D9377933844BQ38902127-F9466224-F889-4175-BF10-86C3F546C9B8
P2860
Interaction between bevacizumab and murine VEGF-A: a reassessment.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@ast
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@en
type
label
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@ast
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@en
prefLabel
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@ast
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@en
P2093
P356
P1476
Interaction between bevacizumab and murine VEGF-A: a reassessment.
@en
P2093
Chingwei V Lee
Claudio Campa
Germaine Fuh
Henry Lowman
Jennifer LeCouter
Napoleone Ferrara
Zhiyong Cheng
P304
P356
10.1167/IOVS.07-1175
P407
P577
2008-02-01T00:00:00Z